RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the ...
Managed Healthcare Executive10h
High-Dose Eylea Shows Unique Properties in nAMD and DME
A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...
Managed Healthcare Executive13h
High-Dose Eylea Offers Longer Treatment Intervals Across Patient Populations with DME
Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...
Regeneron announces three-year data for EYLEA HD Injection 8 mg study
Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...
Regeneron : EYLEA HD Three-Year Results Show Lasting Vision Gains In Diabetic Macular Edema Patients
Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...
The Regeneron effect
Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best High Growth NASDAQ Stock That is Profitable in 2024?
We recently compiled a list of 10 High Growth NASDAQ Stocks That Are Profitable in 2024. In this article, we will look at ...